Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00492050 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. 3 versions Re-verified since Mar 11, 2025, no change to tracked fieldsv36-v38
  2. Completion date: Jun 28, 2024 to Jun 28, 2026v35
  3. 2 versions Re-verified since Feb 15, 2024, no change to tracked fieldsv33-v34
  4. Completion date: Feb 28, 2023 to Jun 28, 2024 Start date: Aug 2006 to Aug 2, 2006v32 Show 1 more changeShow less
    • Start date: Aug 2006 to Aug 2, 2006
  5. Re-verified, no change to tracked fieldsv31
Show 29 earlier versionsHide 29 earlier versions
  1. Results first posted: May 4, 2022 Primary endpoints: 1 to 3 · Enrollment target: estimated 38 to confirmed 46 · Completion date: Feb 28, 2021 to Feb 28, 2023v30 Show 3 more changesShow less
    • Primary endpoints: 1 to 3
    • Enrollment target: estimated 38 to confirmed 46
    • Completion date: Feb 28, 2021 to Feb 28, 2023

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: Feb 2020 to Feb 28, 2021 Completion date: Feb 2021 to Feb 28, 2021v29 Show 1 more changeShow less
    • Completion date: Feb 2021 to Feb 28, 2021
  3. Completion date: Feb 2020 to Feb 2021v28
  4. Re-verified, no change to tracked fieldsv27
  5. Primary completion date: Feb 2018 to Feb 2020 Completion date: Feb 2020v26 Show 1 more changeShow less
    • Completion date: Feb 2020
  6. Primary completion date: Feb 2017 to Feb 2018v25
  7. Primary completion date: Feb 2016 to Feb 2017v24
  8. Primary completion date: Feb 2015 to Feb 2016 Study site revisedv23 Show 1 more changeShow less
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  9. Study description expanded, about 261 wordsv22 See this version in full on ClinicalTrials.gov ↗
  10. Re-verified, no change to tracked fieldsv21
  11. Trial status: Recruiting to Active, Not Recruiting Site details revisedv20 Show 1 more changeShow less
    • Site details revised
  12. Primary completion date: Feb 2014 to Feb 2015v19
  13. Re-verified, no change to tracked fieldsv18
  14. Trial status: Active, Not Recruiting to Recruiting Site details revisedv17 Show 1 more changeShow less
    • Site details revised
  15. Re-verified, no change to tracked fieldsv16
  16. Trial status: Recruiting to Active, Not Recruiting Site details revisedv15 Show 1 more changeShow less
    • Site details revised
  17. Trial status: Active, Not Recruiting to Recruiting Primary completion date: Feb 2013 to Feb 2014 · Site details revisedv14 Show 2 more changesShow less
    • Primary completion date: Feb 2013 to Feb 2014
    • Site details revised
  18. Trial status: Recruiting to Active, Not Recruiting Site details revisedv13 Show 1 more changeShow less
    • Site details revised
  19. 2 versions Re-verified since Aug 24, 2011, no change to tracked fieldsv11-v12
  20. Primary completion date: Feb 2012 to Feb 2013v10
  21. Primary completion date: Feb 2011 to Feb 2012 Study description shortened, about 262 wordsv9 Show 1 more changeShow less
    • Study description shortened, about 262 words

    See this version in full on ClinicalTrials.gov ↗

  22. Study site revisedv8 See this version in full on ClinicalTrials.gov ↗
  23. Primary completion date: Aug 2010 to Feb 2011v7
  24. Secondary endpoints shortened, about 16 wordsv6 See this version in full on ClinicalTrials.gov ↗
  25. Primary completion date: Aug 2009 to Aug 2010 Primary endpoint revised · Interventions: Bortezomib (Drug), Rituximab (Drug) to Bortezomib (Drug), Rituximab (Drug), Valacyclovir (Drug)v5 Show 2 more changesShow less
    • Primary endpoint revised
    • Interventions: Bortezomib (Drug), Rituximab (Drug) to Bortezomib (Drug), Rituximab (Drug), Valacyclovir (Drug)

    See this version in full on ClinicalTrials.gov ↗

  26. Secondary endpoint revisedv4 See this version in full on ClinicalTrials.gov ↗
  27. Primary endpoints: 2 to 1 Primary completion date: Aug 2009 · Completion date: Mar 2008 to not stated · Secondary endpoints: 3 to 1 · 2 morev3 Show 5 more changesShow less
    • Primary completion date: Aug 2009
    • Completion date: Mar 2008 to not stated
    • Secondary endpoints: 3 to 1
    • Study description shortened, about 42 words
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  28. Completion date: Mar 2008 Study arms: 0 to 1 · Study title shortened, about 1 wordv2 Show 2 more changesShow less
    • Study arms: 0 to 1
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main goal of this clinical research study is to learn if Velcade ® (bortezomib) given with rituximab can help to control WM. This drug combination will allow researchers to collect your stem cells in case it is possible to transplant the stem cells as treatment if your WM gets worse. Researchers will also look at the safety and tolerability of this drug combination followed by treatment with other drug combinations.
Trial Details
NCT Number NCT00492050
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Millennium Pharmaceuticals, Inc.
Conditions Waldenstrom's Macroglobulinemia
Enrollment 46 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov